AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its target price reduced by equities research analysts at Morgan Stanley from $26.00 to $22.00 in a research note issued on Friday. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 71.88% from the company’s previous close.
A number of other analysts have also recently commented on the stock. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Wednesday, October 4th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Finally, Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, July 7th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $25.50.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. The business had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. During the same quarter in the previous year, the firm posted $1.45 earnings per share. AMAG Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis.
TRADEMARK VIOLATION WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) Price Target Lowered to $22.00 at Morgan Stanley” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/11/03/amag-pharmaceuticals-inc-amag-price-target-lowered-to-22-00-at-morgan-stanley.html.
A number of institutional investors and hedge funds have recently modified their holdings of AMAG. Karp Capital Management Corp purchased a new stake in AMAG Pharmaceuticals during the first quarter worth about $232,000. OppenheimerFunds Inc. increased its stake in shares of AMAG Pharmaceuticals by 101.1% during the first quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock worth $396,000 after buying an additional 8,836 shares during the period. Principal Financial Group Inc. boosted its holdings in AMAG Pharmaceuticals by 1.6% in the first quarter. Principal Financial Group Inc. now owns 261,929 shares of the specialty pharmaceutical company’s stock valued at $5,906,000 after purchasing an additional 4,008 shares in the last quarter. Wellington Management Group LLP boosted its holdings in AMAG Pharmaceuticals by 233.5% in the first quarter. Wellington Management Group LLP now owns 161,739 shares of the specialty pharmaceutical company’s stock valued at $3,648,000 after purchasing an additional 113,240 shares in the last quarter. Finally, Teachers Advisors LLC boosted its holdings in AMAG Pharmaceuticals by 3.6% in the first quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock valued at $1,399,000 after purchasing an additional 2,164 shares in the last quarter.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.